2) “This study demonstrated a significantly higher humoral immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine (Moderna) compared with the BNT162b2 vaccine (Pfizer-BioNTech), in infected as well as uninfected participants, and across age categories”https://t.co/O7eaxjqg2f
— Eric Feigl-Ding (@DrEricDing) August 31, 2021
4) “A relationship between neutralization level after SARS-CoV-2 vaccination and protection against COVID-19 has been demonstrated. As such, the height of the humoral response after vaccination, which correlates with neutralizing antibody titers, might be clinically relevant.”
— Eric Feigl-Ding (@DrEricDing) August 31, 2021
6) Recently, another study found that Moderna’s vaccine had **2-fold lower risk of breakthrough** #SARSCoV2 infections compared to Pfizer’s in a review of people in the Mayo Clinic Health System in the U.S. from January-July. A preprint. But solid study. https://t.co/YkV7EUyy81 pic.twitter.com/WNpgao9CQ2
— Eric Feigl-Ding (@DrEricDing) August 31, 2021
8) There is still too many unknowns of which vaccine could be better. For example, some data shows AZ vaccines waning less than Pfizer despite Pfizer having higher efficacy early on. Could be a tortoise and the hare situation too. https://t.co/PazZN1NcaX
— Eric Feigl-Ding (@DrEricDing) August 31, 2021
Violin plots of circulating SARS-CoV-2 anti–spike protein receptor-binding domain antibodies in serum samples obtained from participants after they received 2 doses of an mRNA vaccine. Inside each violin plot, the geometric mean is depicted as a point.
A, Difference between participants vaccinated with mRNA-1273 (Moderna) vs those with BNT162b2 (Pfizer-BioNTech).
B, Difference according to previous SARS-CoV-2 infection and the type of mRNA vaccine.
C, Difference according to age and the type of mRNA vaccine in previously uninfected participants. All comparisons were significant at P < .001 except previously infected participants (panel B), which was significant at P = .01.
https://jamanetwork.com/journals/jama/fullarticle/2783797